On January 3, 2022 Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference (Press release, Oncorus, JAN 3, 2022, View Source [SID1234597968]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be available for on-demand viewing beginning Monday, January 10, 2022 at 7:00am ET under the Investors & Media section of Oncorus’ website at View Source A replay of the presentation will be archived on Oncorus’ site for 90 days following the event.

On January 3, 2022 Bio-Techne Corporation (NASDAQ: TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 4:30 p.m. EST (Press release, Bio-Techne, JAN 3, 2022, View Source [SID1234597967]). A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne’s Investor Relations website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 3, 2021 Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) reported that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 9:00 AM ET (Press release, Deciphera Pharmaceuticals, JAN 3, 2022, View Source [SID1234597966]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 30 days following the presentation.

On January 3, 2022 Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) reported that it will participate at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022 (Press release, Concert Pharmaceuticals, JAN 3, 2022, View Source [SID1234597965]). The on-demand presentation will be available beginning at 7:00 a.m. ET on January 10, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. A replay of the conference webcast will be available on Concert’s website for two weeks following the presentation.

On January 3, 2022 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright BioConnect Conference (Press release, Curis, JAN 3, 2022, View Source [SID1234597964]). The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company’s website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.